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The 13th Banff Conference on Allograft Pathology
was held in Vancouver, British Columbia, Canada
from October 5 to 10, 2015. The cardiac session was
devoted to current diagnostic issues in heart trans-
plantation with a focus on antibody-mediated rejec-
tion (AMR) and small vessel arteriopathy. Specific
topics included the strengths and limitations of the
current rejection grading system, the central role of
microvascular injury in AMR and approaches to
semiquantitative assessment of histopathologic and
immunophenotypic indicators, the role of AMR in
the development of cardiac allograft vasculopathy,
the important role of serologic antibody detection in
the management of transplant recipients, and the
potential application of new molecular approaches
to the elucidation of the pathophysiology of AMR
and potential for improving the current diagnostic
system. Herein we summarize the key points from
the presentations, the comprehensive, open and
wide-ranging multidisciplinary discussion that was
generated, and considerations for future endeavors.
Abbreviations: ACR, acute cellular rejection; AECVP,
European Association for Cardiovascular Pathology;
AMR, antibody-mediated rejection; CAV, cardiac allo-
graft vasculopathy; DSA, donor-specific antibodies;
EMB, endomyocardial biopsy; IAMC, intravascular
activated mononuclear cells; ISHLT, International
Society for Heart & Lung Transplantation
Received 17 July 2016, revised 30 September 2016
and accepted for publication 31 October 2016
Introduction
The XIIIth Banff meeting was held October 5–10, 2015 in
Vancouver, British Columbia, Canada in conjunction with
the Annual Scientific Meeting of the Canadian Society of
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Transplantation. A total of 451 delegates from 28 countries
attended the conference, including pathologists, immunol-
ogists, immunogeneticists, and transplant physicians and
surgeons. Heart transplant diagnostics was covered as
part of a dedicated session during the Banff conference.
The main goal was to explore and enhance the common
issues facing the different solid organ transplant groups,
to identify new challenges in thoracic transplant diagnos-
tics, and to foster a collaborative effort among transplant
teams to address these unmet needs. The commonalities
and challenges between kidney and heart transplant rejec-
tion was stressed during the meeting introduction by the
program chairs G. Berry, MD and A. Angelini, MD. This
provided a great opportunity to explore and for building an
integrative network among the different specialties and
solid organ transplant groups. The present report summa-
rizes some of the outstanding issues in heart transplant
diagnostics identified by the panel and members of the
audience together with the main results presented by
experts from centers from different parts of the world and
summary from live discussions. Lastly, this report
addresses proposals for future investigations to elucidate
specific issues in heart transplantation (Table 1).
The Current Diagnosis System for
Antibody-Mediated Rejection: Certainties
and Uncertainties
Currently, the endomyocardial biopsy (EMB) serves as a
primary diagnostic tool for the diagnosis of antibody-
mediated rejection (AMR). The EMB permits the identifi-
cation of AMR-induced tissue damage and the myocar-
dial response to injury. The histopathological changes in
AMR have been formally addressed in the working
formulation for the pathologic diagnosis, grading, and
reporting of cardiac AMR (1) under the auspices of the
International Society for Heart & Lung Transplantation
(ISHLT). Although the authors of this working formulation
recognized that unresolved pathologic questions remain,
the current grading paradigm represents a standardiza-
tion of nomenclature, diagnostic criteria, and a reporting
scheme to facilitate communication between patholo-
gists and clinicians to promote future multicenter studies
and serves as a foundation for pathologic and other
research investigations.
Certainties
pAMR working formulation is a purely pathology-
based approach relying on histopathology and
immunohistochemistry: The main histopathologic
feature of cardiac AMR is microvascular injury with
accumulation of intravascular macrophages representing
microvascular inflammation (Figure 1). As swollen
endothelial cells and T-lymphocytes (2) are part of the
spectrum of cells that can be present in the lumens of
interstitial capillaries and venules in AMR and other
processes, the descriptive term “activated mononuclear
cells” is applied to indicate the difficulty in distinguishing
the cellular components by routine staining alone. The
immunophenotypic component requires multifocal/diffuse
(>50%) C4d capillary endothelial deposition or ≥10%
CD68-positive intravascular macrophages within capillaries
or venules. The grading of AMR is based on the
combination of morphologic and immunopathologic
findings as follows: pAMR 0 negative for pathologic AMR
when both histology and immunohistochemistry are
negative; pAMR 1 (H+) when histopathologic findings are
present and immunohistochemistry negative; pAMR 1
(I+) when histopathologic findings are negative and
immunohistochemistry C4d and /or CD68 is positive;
pAMR 2 or pathologic AMR when both histopathologic
and immunopathologic findings are present; pAMR 3 or
severe pathologic AMR: immunopathologic findings and
myocyte necrosis, microvascular thrombosis, interstitial
hemorrhage and/or polymorphic inflammation are present.
Table 1: Key questions to address in the setting of heart
transplant diagnostics identified by the panel
Microcirculation
inflammation
• Definition and multicenter
assessment of MI grading system:
Reproducibility—exportability,
association with CAV, and outcome.
• Multicenter studies on MI
phenotyping to assess the
heterogeneity of MI and its
relationship with ACR
Chronic
antibody-associated
allograft damage
• Assessment of the influence of
persisting AMR on the cardiac
vasculature from the epicardial
arteries to the interstitial capillaries
• Systematically evaluate myocardial
capillary density after repeated AMR
episodes
• Ultrastructural studies to evaluate
structural capillary changes after
repeated AMR episodes
• Develop uniform terminology for
describing the arterial lesions
comprising CAV
Antibody detection
in cardiac AMR
• Connect antibodies to pathology in
multicenter large-scale studies
• Address anti-HLA and non-anti-HLA-Ab
clinical relevance
• Assess Ab properties with injury
phenotypes, CAV, and outcomes
Molecular approaches
in heart TX
• Molecular phenotype of AMR
• Connect antibodies and pAMR ISHLT
categories with gene signatures in
EMB
• Molecular phenotype of ACR
Ab, antibody; ACR, acute cellular rejection; AMR, antibody-
mediated rejection; CAV, cardiac allograft vasculopathy; ISHLT,
The International Society for Heart & Lung Transplantation;
MI, microvascular injury; pAMR, pathologic antibody-mediated
rejection; TX, transplant.
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It is a pathologic grading scheme independent of
clinical and serologic data: One of the main
conclusions of the 2010 ISHLT consensus meeting on
AMR (3) was that pAMR would be a purely pathologic
diagnosis akin to the diagnosis of acute cellular rejection
(ACR), without the requirements of donor-specific
antibodies (DSA) and allograft dysfunction.
Currently, it is a diagnostic working formulation rather
than a predictive or prognostic scheme: Except for
pAMR3 or severe AMR that is usually associated with
marked cardiac dysfunction, the other AMR grades
(pAMR0 to pAMR2) have not been correlated with DSA
levels, immediate prognosis, or clinical AMR in prospective
studies and importantly, have not yet established
treatment thresholds (4).
It is a consensus working formulation: pAMR
working formulation resulted from the cumulative work
of four consensus meetings: Allograft Pathology
Conference in Banff 2009 and ISHLT meetings in
Chicago, IL in 2010, San Diego, CA 2011, and Prague,
Czech Republic 2012. Among its designated purposes
will be a standardized format for reporting AMR in
institutional programs and for multicenter studies (1,4).
It is quite easy to use and learn: It has been validated
by a reproducibility study on digitalized slides hosted on
a web site testing 24 AMR-positive EMBs among a
panel of 13 pathologists (1). A tutorial for pAMR learning
is now available at http://scvp.net/amr/index.html.
pAMR working formulation is supported by scientific
evidences: pAMR grades are correlated with DSA and
mTOR pathway activation in endothelial cells (5) and a
limited number of retrospective clinical studies (6).
Uncertainties
Although the pAMR working formulation is now widely
used as a diagnostic tool for cardiac AMR, there are limi-
tations that will need to be addressed in future studies.
These could include refinement of diagnostic thresholds,
morphologic criteria, and importantly, clinicopathologic
correlations to determine indications for therapeutic
intervention.
A B C
D E F
Figure 1: Main histopathologic and immunophenotypic features of cardiac AMR on endomyocardial biopsies. (A) Intravascular
accumulation of intravascular mononuclear cells within the myocardial capillaries. H&E stain; original 920. (B) Diffuse hypercellularity
within the myocardium resulting in a “busy pattern” at low magnification. H&E stain; original 910. (C) Histopathology cannot clearly
differentiate the cell types accumulating in intravascular location (arrow). They are referred to as intravascular activated mononuclear
cells. H&E stain; original 940. (D) Diffuse labeling of capillaries with C4d antibody by immunohistochemistry. Formalin-fixed paraffin-
embedded biopsy; original 940. (E) Diffuse labeling of capillaries with C4d antibody by immunofluorescence. Frozen tissue;
original 940. (F) Many intravascular CD68-positive macrophages. Formalin-fixed paraffin-embedded biopsy; original 940. AMR, anti-
body-mediated rejection.
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The morphologic basis of pAMR, intravascular
activated mononuclear cells (IAMC) and positive C4d
and/or CD68 immunohistochemistry will require
quantitative assessment: The threshold for which
IAMC are considered significant for the possibility of AMR
in hematoxylin and eosin (H&E)–stained sections has not
been formally established. In the majority of cases the
morphologic changes are diffusely present throughout the
biopsy pieces (1). The clinical significance of focal or
patchy histopathologic changes, while uncommon, is
not understood. The establishment of a numeric threshold
will require a formal study. The immunopathologic
assessment of the thresholds for C4d and CD68 at 50%
and 10%, respectively, were established by agreement of
the participants in the working formulation. These
parameters will need validation to better characterize the
morphological diagnosis of AMR and establish a clinically
relevant grading system.
The application of pAMR working formulation can
present technical challenges: A major component of
pAMR is the presence of mononuclear cells within the
lumens of interstitial capillaries. The intravascular location of
cells can be difficult to recognize by routine histology or by
immunohistochemistry for a variety of technical and
interpretative reasons as discussed in the working
formulation (1). Double labeling with an endothelial marker
(CD31 or CD34) has limited availability in many practices. An
expanded repertoire of antibodies including PU.1 (BD
Bioscience, San Jose, CA) may be helpful to distinguish
intravascular from extravascular locales. The true nature of
IAMC may not be apparent by routine H&E staining as the
possible cell types include endothelial cells, lymphocytes,
and macrophages among others. Phenotyping of the
IAMC by immunohistochemistry is mandatory since
only macrophages are assessed in the evaluation of AMR
(2). The presence of intravascular lymphocytes and
occasional macrophages not uncommonly accompany the
perivascular and interstitial infiltrates of ACR. For this
reason the evaluation of IAMC on EMB is assessed away
from foci of ACR to avoid the misinterpretation of
intravascular cells. Lastly, there are very few studies
examining the pathologic differences between early-onset
and late AMR (7).
Entities that can complicate the interpretation of
pAMR: In addition to the interpretative issues that ACR
raises in assessing AMR, the issue of mixed ACR and
AMR adds additional complexity. Depending on the
patient population, the incidence of mixed ACR-AMR is
significant and the prognostic implications have been
reported by a number of groups (8). One of the
immunophenotypic criteria for AMR is deposition of C4d
on the capillary endothelium. The issue of C4d-negative
AMR was recently raised by Tible and colleagues (5).
The incidence and significance of this pattern are
currently unknown but draw some parallels with the
renal experience and warrant further investigation.
The correlation between pAMR and its
pathophysiology and clinical phenotypes remains
poorly understood: The correlation of the pAMR grades
with treatment regimens, molecular characteristics,
long-term allograft outcomes, and patient survival is
currently limited to only a few retrospective studies.
These will require detailed prospective studies and
ideally, multicenter projects. In addition, complementary
approaches using IHC immunohistochemistry-based
biomarkers (5,9,10) in pAMR as well as tissue-based
transcriptomics are under active investigation to
determine whether the pAMR grades correlate with
distinct allograft injury phenotypes, commonalities/
overlaps/and specificity (4).
Implementing a Microcirculation
Inflammation Grading System in EMB
(Figure 2)
Microvascular inflammation (MI) is recognized as a key
indicator of AMR in kidney and heart allografts. As dis-
cussed above, the primary histopathologic marker in the
assessment of cardiac microvascular injury (MI) is the
IAMC, which include both intravascular macrophages and
swollen endothelial cells.
This consensus reflected the current state of knowledge
and experience in the morphology of AMR at that time,
but the group was aware of the many questions left
open such as (i) evaluating IAMC is at present purely bin-
ary (presence or absence); (ii) in many cases, distinguish-
ing between intravascular macrophages and swollen
endothelial cells or other cell types, i.e. lymphocytes, is
difficult if the phenotype of intracapillary cells is not rou-
tinely assessed by immunohistochemistry; (iii) recognizing
the predominant pattern of intravascular versus extravas-
cular localization of inflammatory cells may be challenging.
This distinction is important as it is utilized to differentiate
ACR from AMR.
A recent pilot study (2) from the European Association
for Cardiovascular Pathology (AECVP) focused on the
inflammatory burden (IB) in 35 cases of pAMR1 or
pAMR2 cases without significant ACR (ISHLT 0 or ≤ 1R),
using an antibody panel consisting of the complement
C4d, pan-T-cell CD3-T, pan-B-cell CD20, macrophage
CD68, and a plasma cell marker, CD138. The primary
findings in this study included the following: (i) the
number of intracapillary inflammatory cells vary greatly
between AMR cases (even in cases classified in the
same categories); (ii) macrophages are not the sole cell
type present in AMR, as a variable proportion of T-cells
can be present and fewer B-cells and plasma cells;
American Journal of Transplantation 2017; 17: 42–53 45
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Figure 2: Microcirculation inflammation in cardiac AMR. (A) CD68-positive intravascular mononuclear cell in several capillaries
reflecting their monocyte–macrophage lineage. In this field, most of the labeled cells are clearly intravascular. CD68 immunohisto-
chemistry; original 940. (B) CD3-positive intravascular mononuclear cell in capillaries reflecting that T-lymphocytes are a significant cell
component of the intravascular activated mononuclear cells in AMR. CD3 immunohistochemistry; original 940. (C) Double labeling
using an endothelial marker (CD31) in red and a T-lymphocyte marker (CD3) in brown demonstrating the intravascular location of the
CD3-positive cells. This pattern is different from the T-lymphocyte riming around capillaries and venules in cellular rejection. Double
CD31-CD3 immunohistochemistry; original 940. (D–F) Low-magnification views showing different intensities of the extension of the
microcirculation inflammation in biopsies: D– minimal; E–focal; F–diffuse. Hematoxylin and eosin (H&E) stain; original 910. (G–I) Higher
magnification views showing different patterns of accumulation of the intravascular activated mononuclear cells (IAMC) in biopsies:
G–rare IAMC; H–some IAMC; I–many IAMC forming intravascular plug. H&E stain; original 920. AMR, antibody-mediated rejection.
Figure 3: Spectrum of cardiac allograft vasculopathy (from epicardial arteries to myocardial capillaries). (A) Allograft epicardial
coronary artery showing intimal and adventitial inflammation (hematoxylin and eosin [H&E], 9100). (B) Allograft epicardial coronary
artery showing intimal fibrosis with shallow fibrin thrombus at the luminal aspect and some entrapped fibrin deeper in the intimal wall
(arrows) (H&E, 920). (C) Allograft epicardial coronary artery with less intimal thickening but dramatic adventitial lymphoid aggregate
(asterisk) (H&E, 920). (D) Allograft epicardial coronary artery showing advanced narrowing with a slit-like lumen; there is very little out-
ward remodeling of the vessel wall (H&E, 940). (E) Allograft endomyocardial biopsy photomicrograph after computer-assisted image
analysis for capillary density. This case showed reduced capillaries (CD34 stain, 9200) (MVD, microvascular density). (F) Allograft
endomyocardial biopsy photomicrograph after computer-assisted image analysis for capillary density. This case showed preserved cap-
illary density (CD34 stain, 9200). (G) and (H) Electron photomicrographs of allograft myocardium showing an interstitial capillary with
basement membrane multilayering (arrows) (original 94000 and 910 000).
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(iii) extravascular pericapillary inflammatory cells consisting
of both lymphocytes and macrophages are frequently
observed in the presence of intracapillary hypercellularity.
The authors promoted the need for further studies to
address these issues in large collaborative multicenter
studies. Some interesting points addressed by the study
A B
C D
E F
G H
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warrant highlighting: (i) the heterogeneity of IB in cardiac
pAMR in general, and in early and late or very late
pAMR; (ii) the presence of inflammatory cell gradients
and heterogeneous cell profiles in pAMR grades; (iii) the
complex interplay between cellular- and antibody-
mediated immunological processes, with the reciprocal
influence of ACR and AMR, and consequently the issue
of mixed ACR-AMR rejection. The ISHLT working group
proposed to address the issue of mixed rejection in sub-
sequent multicenter projects. At the 2016 Washington
ISHLT Meeting, the Pathology Council proposed that the
IB study be extended to a wider multicenter study to
address these points and to focus on mixed rejection in
more detail.
Another issue discussed at Banff 2015 was the assess-
ment of MI using a semiquantitative histologic grading
system. In kidney transplantation, a semiquantitative his-
tologic evaluation of MI that combines glomerulitis and
peritubular capillaritis scores is now part of the Banff
schema for the diagnosis of renal AMR. High-grade MI
has been associated with worse renal allograft outcome
in some studies (11). The French transplant group
reported its preliminary data applying a semiquantitative
grading scheme to assess MI severity. The score incor-
porates both the extent (percentage of the specimen
involved) and pattern (maximum number of inflammatory
cells in the most affected capillaries or venules) of IAMC.
The preliminary results showed an association between
the MI grade and AMR disease activity measured by
molecular analysis. During the group discussion it was
recognized that the MI grading scheme should be further
evaluated in a multicenter study to address its repro-
ducibility and correlation with allograft outcomes. At the
subsequent 2016 ISHLT meeting in Washington, DC, the
Pathology Council proposed that the project on histologic
MI grading be included in a multicenter study, with par-
ticular attention to the issues of sensitivity and specificity
of histologic aspects in MI, inter-, and intraobserver
reproducibility, and correlation with current AMR histo-
logic criteria, clinical, and immunologic findings and ulti-
mately with outcome data.
Assigning Specific Phenotypes of
Alloimmune-Mediated Vascular Injury
(Figure 3)
The recognition of AMR in cardiac allografts has evolved
over the last quarter century (12). Originally it was recog-
nized as a cause of early allograft dysfunction but
late-onset AMR is now encountered. Furthermore,
asymptomatic AMR has been reported, although the clin-
ical significance remains controversial (13–15). The natu-
ral history of AMR and specifically the cumulative effects
of repetitive AMR episodes on allograft function and sur-
vival have been addressed in a limited number of studies
(16).
AMR affects the endothelium throughout the heart and
the morphologic manifestations vary according to vessel
caliber. The epicardial coronary and penetrating arteries
show alterations termed “cardiac allograft vasculopathy
(CAV)”. The small vessels and microcirculation are also
affected, initially manifesting as MI with IAMC (1) with
progression to loss of capillaries per unit area (microvas-
cular density) (17) and structural changes (thickening)
(18).
Morphologic manifestations of CAV in epicardial and
myocardial muscular arteries are both inflammatory and
proliferative in nature. Inflammation may be limited to
the intimal layer (endothelialitis or intimitis) or extend
transmurally. Shallow nonocclusive thrombus accompa-
nies the inflammatory lesion in some cases. The prolifer-
ative lesions are confined to the intimal layer, but differ
from native atherosclerosis by their concentric distribu-
tion, limited lipid deposition, and absence of outward
remodeling of the media and adventitia (19,20).
CAV has been associated with AMR in published studies
for more than two decades now (21), but the stringency
of that association as well as the apparent correlation
between CAV and other non-AMR factors suggests a
more complex interplay (21–24). At the capillary level,
the classic features of AMR are endothelial swelling and
accumulation of intravascular macrophages. Complement
activation, characterized by C3d and C4d deposition in
tissue sections, is a key component of AMR, but may
not be demonstrable in every case and is then captured
in the AMR grading scheme as pAMR 1(H+) (1). This
may be explained, in part, by the decrement in myocar-
dial capillary density and morphologic alteration of capil-
laries manifesting as multilayering of their supporting
basement membranes in cases of repetitive microvascu-
lar injury (25).
Much work remains to be performed to unravel the
immunobiology, morphology, and pathophysiology of
AMR’s influence on the cardiac vasculature from the epi-
cardial arteries to the interstitial capillaries. While many
studies have highlighted a correlation, other studies have
not shown a link between these processes (26). Addi-
tional clinical and pathologic studies along with more
robust animal models will be needed to clarify the mor-
phologic, immunopathologic, serologic, and molecular
components of AMR. The current diagnostic criteria and
grading scheme serve as an initial platform for this work.
As emphasized by the working formulation of the ISHLT,
there will be a need to reconvene in the future to reas-
sess the concepts and approaches to the diagnosis of
AMR. Lastly, there is now a standardization of nomencla-
ture for the angiographic diagnosis and classification of
CAV, but there remains a need for uniform pathologic
terminology. The renal transplant community has estab-
lished morphologic criteria for “acute” and “chronic”
AMR (27). In the cardiac literature the terms are often
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applied according to temporal presentation. The term
“chronic rejection” has been used inconsistently in the
literature, often to indicate late onset (or recognition) of
AMR rather than AMR persisting over time. Likewise,
the term “rejection” has been questioned since there
may be no demonstrable impairment of graft function
and nonimmune mechanisms may play an important
mechanistic role in these changes. “Chronic antibody-
associated allograft damage” was proposed as a term
appropriately encompassing the changes described
herein. More precise terminology and definitions will be
needed to establish databases and design studies exam-
ining “early-onset acute,” “late-onset acute,” “recur-
rent,” “persistent,” and “chronic” AMR.
The Place of Antibody Detection in AMR
Assessment in Heart Transplantation
The current ISHLT grading system for cardiac AMR is
based exclusively on pathologic evidence, without requir-
ing the additional features of clinical graft dysfunction
and/or presence of donor-specific HLA or non-HLA anti-
bodies (1). That said, the vital role and importance of clin-
ical information and serologic data in the overall
assessment of the patient is heavily underscored. Cur-
rently, most patients with suspected AMR will undergo
evaluation to identify the causative agent, namely, HLA
or non-HLA antibodies. Numerous studies have shown
that cardiac AMR diagnosis is associated with donor-
specific HLA antibodies (DSA) and cardiac transplant
survival is lower in recipients with DSA at the time of
AMR (3,16,28,29). Furthermore, DSA are associated with
progression to cardiac allograft vasculopathy and reduced
long-term cardiac allograft survival (23,30). DSA testing
shows outstanding sensitivity and negative predictive
value for biopsy-diagnosed AMR in both adult and pedi-
atric cardiac transplant recipients (31). In posttransplant
care, quantitative DSA should be an essential component
in the surveillance for AMR. Moreover, the presence of
mixed AMR and ACR concurrently (8) may be explained
by the fact that antibodies mediate leukocyte recruitment
to the allograft via IgG-Fc receptor-mediated effector
functions (32). Table 2 summarizes outstanding ques-
tions identified and potential recommendations made by
the Ab expert panel. As the immunologic testing and
interpretation of test results become more standardized
across transplant centers, some investigators have raised
the issue of reintroducing HLA DSA and non-HLA anti-
body testing information for use in the diagnosis of AMR
and for risk assessment of persistent AMR and CAV (3).
Whether there is currently sufficient standardization and
consensus among immunologists and clinicians is contro-
versial and awaits future investigation, consensus analy-
sis, and debate.
New advances in antibody testing by introduction of
multiplex-bead array assays have revolutionized the field
and significantly improved the sensitivity and precision of
circulating DSA detection. The benefits and limitations of
the solid-phase assay using single antigen beads have
been captured in many reviews (33–39). In Table 3 the
American Society for Histocompatibilty and Immuno-
genetics HLA panel experts describe problems that may
impact test interpretation and provide potential solutions
to avoid false positive or incomplete results that may
influence patient management. The continuous dialogue
between the clinical laboratory and clinicians is the key
to provide the most accurate information. The clinical
impact of non-HLA-specific antibodies either alone or
Table 2: Prospects for implementing HLA Ab detection into the AMR classification in cardiac transplantation: outstanding question
identified and potential recommendations made by the Ab expert panel
Questions Recommendations Definitions
What is the optimum
timing of DSA testing
posttransplantation?
Stratify the patients based on risk for AMR and monitor:
 High and intermediate risk with each biopsy
early posttransplant, 3, 6, 9, 12 months first year
and yearly if no clinical indication.
 Low-risk minimum 3, 6, 12 months, yearly after and
anytime clinically indicated
 High risk: presence of DSA at the
time of transplant
 Intermediate risk: presence of DSA
in historical samples
 Low risk: no DSA detected
When DSA should be treated?  Increased level (titer and MFI) of persistent
DSA should be biopsied to rule out subclinical
rejection.
 Strong correlation of persistent DSA with graft
dysfunction
 Level DSA levels assessed by MFI
strength and/or titration of sera
 Persistent DSA: presence of DSA in
serial samples
 Transient DSA: Presence of DSA
only in one sample
Should DSA testing be performed
with diagnosis of pAMR ?
 Testing for DSA presence and level (HLA and
non-HLA) should be performed to:
o correlate with severity of pAMR
o assess efficacy of treatment
Ab, antibody; AMR, antibody-mediated rejection; DSA, donor-specific antibodies; MFI, mean fluorescence intensity.
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together with DSA recently has been an intense area of
research in solid organ transplantation (40,41). Newly
developed enzyme-linked immunosorbent assay solid-
phase assays have allowed a reliable means of detecting
antibodies to the G protein–coupled receptors, angioten-
sin-II type 1 receptor (AT1R) and endothelin type A recep-
tor (ETAR). These reagents together with the availability
of proficiency testing programs have allowed their imple-
mentation in testing for clinical transplantation. Elevated
levels of AT1R and ETAR have been associated with early
onset of microvasculopathy as well as with AMR and
ACR (42). Furthermore, freedom from AMR and/or ACR
was observed to be significantly decreased when both
de novo DSA and increased AT1R antibodies levels were
considered (43). A growing body of evidence supports
the role of alloimmune and autoimmune mechanisms
involving antibodies directed against non-HLA antigens in
transplant allograft damage (44–46).
Need for Complementary Tissue Molecular
Approaches
The ISHLT working formulation has taken important
steps to improve the pathological diagnosis and uniform
reporting of AMR. The panel and live discussion at the
Banff conference discussed some of the issues that
remain unresolved such as regarding the pathophysiology
of heart rejection and how activity, injury degree, and
stage could be improved. As discussed in an earlier sec-
tion, the emerging role of molecular diagnostics is a
potential avenue to further our mechanistic understand-
ing of ACR and AMR, to help refine our current diagnos-
tic categories and elucidate thresholds for therapeutic
intervention. Molecular diagnostics has been utilized in
renal transplantation to identify the subset of C4d-
negative patients with AMR. There is currently limited
but evolving data in the cardiac AMR arena. Preliminary
data from the Paris-Bologna-Edmonton collaboration
were presented showing the potential of gene expres-
sion in EMB to map the molecular architecture of AMR
and its correlation with disease activity. The commonali-
ties between cardiac and kidney transplant rejection sug-
gests the molecular microscope as an important
approach that should be actively investigated by trans-
plant research groups. The panel cautioned about the
need for a comprehensive clinical and pathologic detail
including state-of-the-art DSA assessment using sensitive
assays and accepted thresholds such as mean fluores-
cence intensity before a specific set of genes could be
correlated to specific allograft injury phenotypes. In this
setting, it was also suggested that as there is a morpho-
logic and immunophenotypic spectrum for AMR, it is
unlikely that a single gene will be specific and that this
very complex undertaking will require transcriptomics
data based on methodical approaches such as classifiers,
machine learning, etc. Finally, the panel supported and
encouraged collaborations within centers and promoted
multicenter studies.
Summary and Future Directions
The diagnostic, therapeutic, and mechanistic landscapes
of allograft rejection have evolved and changed dramati-
cally over the last 25 years. The incidence of clinically
significant ACR has diminished in most transplant cen-
ters, with 5% to 15% of EMB being positive for T cell–
mediated rejection of the total of EMB performed in the
first year posttransplant. Cardiac allograft vasculopathy
remains the persistent impediment to long-term allograft
and patient survival. While the angiographic findings and
corresponding histopathologic features have been well
known for many decades, the immunobiology continues
to evolve through clinical and animal studies. The role of
the EMB has emerged as a useful investigative tool. It
Table 3: Prospects for implementing HLA-Ab detection into the AMR classification in cardiac transplantation: limitations and potential
solutions
Problem Interpretation Resolution
HLA-Ab to denatured antigens False positive results: HLA-Ab to cryptic
epitopes, clinically irrelevant
Repeat testing after acid treatment of SAB;
surrogate crossmatch
Intrinsic and extrinsic factors
inhibiting the SAB assay
False low MFI or negative results: due to
inhibition of SAB assay
Dilution of sera pretesting, adsorption,
inhibition of C1q, addition of EDTA, heat
treatment to remove and uncover the real
reactivity
Low MFI on SAB resulting in
higher reactivity using cellular
targets
False low MFI: DSA to a shared target present
on multiple beads
Adequate analysis of specific DSA epitope
Using MFI to evaluate level and
strength of DSA for risk
stratification
Low or high MFI level of DSA may not
correlate with risk of AMR, or response to
treatment following antibody removal
therapies
Modified SAB assay to distinguish between
complement and noncomplement binding
DSA and determining titer of DSA (serial
dilutions of patient sera)
Ab, antibody; AMR, antibody-mediated rejection; DSA, donor-specific antibodies; EDTA, ethylenediamine tetraacetic acid; MFI, mean
fluorescence intensity; SAB, single-antigen bead.
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was once thought that the myocardial changes were sta-
tic and merely reflected effects of larger epicardial dis-
ease; however, the focus has now shifted to the
microvascular changes in the capillaries, venules, and
arterioles and their role in the clinical and pathophysio-
logic consequences of CAV. There is a need for more
precise terminology, definitions, and classifications of the
changes at the microvascular level and uniformity in
approaches, morphometrics, and immunohistochemical
analysis.
The role of AMR in the initiation of allograft dysfunction
and the development of CAV has also matured. The
working formulation for the diagnosis and reporting of
AMR has now been utilized for less than 5 years and the
results from single-center studies are limited. Its original
aim to provide a framework for clinical and investigative
endeavors should remain, with the intended goal to ree-
valuate its functionality in the future based on published
data. That said, the rapidly expanding influence of pro-
teomics, transcriptomics, and other molecular diagnostic
approaches will likely illuminate and clarify our current
concepts.
The overlap of clinical, histopathologic, and immunophe-
notypic features of AMR in the different solid organ
transplant groups encourages the multidisciplinary and
transdisciplinary endeavors of the Banff Conference.
Much can be learned from each group. In acute renal
AMR, like its cardiac counterpart, microvascular injury is
centered on the microvasculature such as the peritubular
capillary injury and the glomerulitis resulting in endothelial
alterations, interstitial edema, and in severe cases, vas-
cular thrombosis and fibrinoid necrosis (27). The cardiac
morphologic spectrum has been described in detail in
earlier sections of this report. The acute manifestations
of AMR in the liver allograft are evolving but include
endothelial swelling in the portal veins, venulitis, and cap-
illaritis with hepatocyte ballooning and cholestasis (47).
Chronic AMR has been defined and criteria have been
enumerated in the renal allograft (27). They include
glomerular double contours, peritubular capillary multilay-
ering of basement membranes, interstitial fibrosis, tubu-
lar atrophy, and intimal proliferation of arteries. In the
liver interface hepatitis, lobular inflammation, periportal
and sinusoidal fibrosis, and vasculopathy have been
described (47). The cardiac allograft currently does not
have a formal “chronic AMR” designation, but there is
an overlap of findings with the kidney and liver. These
similarities provide an impetus and directions for further
investigations.
This rich array between the different solid organ groups
provides a multitude of directions and opportunities for
transdisciplinary collaborations. The molecular discoveries
in kidney AMR, including the category of C4d-negative
AMR (48), are currently being evaluated in some cardiac
groups. Together with future clinical, pathologic,
serologic, and other discoveries, these molecular data
may help to clarify clinical, therapeutic, predictive, and
prognostic information. Ultimately, the goal of overcom-
ing transplant vasculopathy and graft loss in the different
transplant groups may yet be realized. To this end, col-
laborations among transplant groups and societies will
expedite these goals.
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